Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
36 Leser
Artikel bewerten:
(0)

Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland

FREDERICK, Md., Oct. 2 /PRNewswire/ -- The Matan Companies has teamed up with Federal Capital Partners (FCP) to complete the financing for the development of the National Cancer Institute's 330,000 square foot Advanced Technology Research Facility (ATRF) at Riverside Research Park in Frederick, Maryland. The state-of-the art 200 million dollar office and laboratory facility will commence construction immediately and is slated for delivery in mid 2011. As part of the larger 177 acre Riverside Research Park, the National Cancer Institute's 62 acre campus will have expansion capacity for another 570,000 square feet, reserved for life-science and advanced technology partner organizations. "This site will be the center of an intensive new effort to bring together government, industry, academic, and nonprofit partners, working side-by-side, utilizing technological resources second to none, to more rapidly translate our latest genetic and molecular discoveries about cancer into effective new treatments that benefit patients," said John E. Niederhuber, M.D., director of the National Cancer Institute. With SAIC-Frederick, Inc. as its prime contractor, the new facility will be the only Federally Funded Research and Development Center (FFRDC) in the country focused exclusively on biomedical research and development, and concerted technology and R&D partnership efforts toward reducing the burden of cancer.

Matan and FCP partnered to secure the 52 million dollar construction financing from Wells Fargo Bank and US Bank. "Today's financing environment demands creative approaches to bring large, high profile projects like this to the market. The ATRF is one of the largest private biotech developments in the country to secure construction financing and it is a credit to everyone involved," stated Mark Matan, Principal of the Matan Companies. Matan Companies will develop and manage the project.

"We are incredibly excited to have formed this partnership with the Matan Companies to bring this very important project to fruition," said Esko Korhonen, Managing Partner of FCP. "The diligent work by our teams resulted in consummating a great financing package and we appreciated the opportunity to work with Wells Fargo, US Bank, Jones Lang LaSalle and Cassidy & Pinkard to get this deal completed."

Cassidy and Pinkard helped to secure the equity and debt for this transaction and Jones Lang LaSalle represented the Tenant.

About Riverside Research Park

Riverside Research Park is the first biomedical research and development park of its kind in Frederick Maryland. The 177 acre site has all necessary infrastructure and utilities in place and is ready to build. Riverside delivered its first tenant in the Spring of 2008, a 54,000 sf facility for Charles River Labs. Riverside can accommodate up to 1.8 million square feet of lab, R &D, and office space. "Frederick has a vibrant biotech community servicing NIH, the National Cancer Institute and Fort Detrick, but until now there hasn't been a destination for these companies to come together in a collaborative campus type environment in this market. Riverside Research Park provides just that and there has been a very high level of interest from companies looking to co-locate with the National Cancer Institute" said J.P. Matan, Director of Leasing for Matan Companies. Located within the city limits of Frederick and less than three miles from the main gates of Fort Detrick, Riverside is uniquely positioned to provide private sector companies, government agencies, and universities a secure and collaborative work environment. Abundant green space, water features, walk/jogging trails, courtyards, and chance meeting spaces will all add to the collaborative work environment and campus like feel of Riverside Research Park. For more information please visit: http://www.riversideresearchpark.com/

About Federal Capital Partners

Founded in 1999 by partners Esko L. Korhonen and Lacy I. Rice, Federal Capital Partners (FCP) is a real estate investment and development company headquartered in Washington DC. Other partners include Alex Marshall and Tom Carr, former Chairman and CEO of CarrAmerica Realty Corp. who joined FCP as a partner in early 2007. Since its inception, FCP has acquired more than $1.2 billion of real estate assets consisting of multi-family, office, retail and industrial assets.

About Matan Companies

Headquartered in Frederick Maryland for over 30 years, Matan Companies is one of the regions premier commercial real estate and development firms. Matan's primary geographic focus is Frederick, Maryland and the I-270 Corridor. Matan's current portfolio consists of over 3.2 million square feet in 30 buildings with an additional 3 million square feet in the development pipeline.

About NCI-Frederick and SAIC-F

With SAIC-Frederick (SAIC-F) as its prime contractor, NCI-Frederick, is home to a cadre of researchers studying cancer and HIV/AIDS and is host to NCI's Advanced Technology Program, which encompasses nanotechnology, high-performance computing, genomics, and biomedical imaging, among other areas. SAIC-F, a wholly owned subsidiary of Science Applications International Corporation (SAIC), a Fortune 500® company - is the operations and technical support contractor for the National Cancer Institute's research and development center in Frederick, Md. "The NCI has identified an urgent need to convert basic research findings into effective cancer treatments that can be delivered to patients right away," said Larry O. Arthur, Ph.D., president of SAIC-Frederick. "The consolidation of our operations into modern facilities will enable us to do just that, with the specific goal of shortening timelines, reducing costs, and increasing productivity--all of which will benefit cancer patients and people at risk for cancer." More information about the NCI's Advanced Technology Partnerships Initiative (ATPI) can be found at http://www.atpihome.com/.

NCI at Riverside Research Park Building Rendering: https://www.box.net/shared/static/r2a6uoimhs.tif

Photo Credit: CUH2A- Architect, Annapolis Web Publishing- Rendering

Matan Companies

CONTACT: Noelle Schilling, +1-301-815-9980 Cell +1-301-471-7552,
nschilling@mataninc.com; Additional Contacts: Esko Korhonen, Federal Capital
Partners, +1-202-386-7160, esko@fcpdc.com; Frank Blanchard, SAIC-F,
+1-301-846-1893, Blanchard@mail.nih.gov; Joe Carter, Wells Fargo,
+1-202-303-3016, carterjl@wellsfargo.com; Jeff Jacobson, US Bank,
+1-703-442-5482, Jeffrey.jacobson@usbank.com; Paul Collins, Cassidy & Pinkard,
+1-202-463-2100, pcollins@cassidypinkard.com; Pete Briskman, Jones Lang
LaSalle, +1-301-214-1144, Pete.Briskman@am.jll.com

Web Site: http://www.mataninc.com/

© 2009 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.